KemPharm Company Profile (NASDAQ:KMPH)

Analyst Ratings

Consensus Ratings for KemPharm (NASDAQ:KMPH) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $28.50 (549.20% upside)

Analysts' Ratings History for KemPharm (NASDAQ:KMPH)
Show:
DateFirmActionRatingPrice TargetActions
6/14/2016Oppenheimer Holdings Inc.Reiterated RatingBuy$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/14/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/15/2015Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for KemPharm (NASDAQ:KMPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/12/2016Q1($0.46)($0.20)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q4($0.50)($0.64)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.42)($0.68)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.47)($2.45)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/27/2015Q1($0.49)($2.50)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for KemPharm (NASDAQ:KMPH)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.56)($0.56)($0.56)
Q2 20161($0.59)($0.59)($0.59)
Q3 20161($0.66)($0.66)($0.66)
Q4 20161($0.69)($0.69)($0.69)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for KemPharm (NASDAQ:KMPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for KemPharm (NASDAQ:KMPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/29/2016Travis C MickleCEOBuy2,450$14.57$35,696.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for KemPharm (NASDAQ:KMPH)
DateHeadline
07/23/16 08:49 AMKemPharm, Inc. (NASDAQ:KMPH) soared 6.38%: Flexible Solutions International Inc. (NYSEMKT:FSI), Tractor Supply ... - KC Register
07/23/16 08:49 AMKemPharm Inc (NASDAQ:KMPH): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 05:03 PMHow Analysts Feel About KemPharm Inc After Today's Huge Increase? - Press Telegraph
07/21/16 05:03 PMChecking in on Stock Volatility for: KemPharm, Inc. (NASDAQ:KMPH) - Engelwood Daily
07/21/16 05:03 PMEquity Roundup: Stock Performance Focus on KemPharm Inc (NASDAQ:KMPH) - Press Telegraph
07/20/16 02:58 PMEarnings Focus and Crowd Sourced Sentiment Review for KemPharm Inc (NASDAQ:KMPH) - TGP
07/17/16 09:13 AMHow Many KemPharm Inc (NASDAQ:KMPH)'s Analysts Are Bullish? - Consumer Eagle
07/16/16 04:34 PMShares Experiencing a Downtrend: KemPharm, Inc. (NASDAQ:KMPH) - TGP
07/15/16 08:54 AMKemPharm Inc (NASDAQ:KMPH) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/15/16 08:54 AMAnalyst Target and Average Rating Watch: KemPharm Inc (NASDAQ:KMPH) - Press Telegraph
07/14/16 05:04 PMKemPharm (KMPH) Completes Key Meetings with FDA forKP201/IR and KP415; Sees Submitting INDs in H216 - StreetInsider.com
07/14/16 05:04 PMTrading Performance and Target Watch for KemPharm Inc (NASDAQ:KMPH) - Press Telegraph
07/14/16 03:48 PMKemPharm Completes Key Regulatory Meetings with FDA for KP201/IR and KP415 - [at noodls] - CORALVILLE, Iowa, July 14, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today ...
07/13/16 05:14 PMKemPharm Inc (NASDAQ:KMPH) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/11/16 04:55 PMKemPharm, Inc. (KMPH) Updated Price Targets - FTSE News
07/11/16 04:55 PMStock Volatility Focus for: KemPharm, Inc. (NASDAQ:KMPH) - Engelwood Daily
07/11/16 04:55 PMShares Dipping Lower in Session: KemPharm, Inc. (NASDAQ:KMPH) - Telanagana Press
07/09/16 08:15 AMWere Analysts Bearish KemPharm Inc (NASDAQ:KMPH) This Week? - Engelwood Daily
07/08/16 04:59 PMIncreased Volatility on Shares of: KemPharm, Inc. (NASDAQ:KMPH) - Engelwood Daily
07/08/16 07:46 AMCan KemPharm Inc (NASDAQ:KMPH) Improve on the Earnings Front? - Engelwood Daily
07/08/16 07:46 AMCompany Stock Focus for KemPharm Inc (NASDAQ:KMPH): Which Way Will Shares Head? - Press Telegraph
07/07/16 04:55 PMIncreased Volatility Watch for: KemPharm, Inc. (NASDAQ:KMPH) - Engelwood Daily
07/05/16 04:44 PMShare Volatility in Focus: KemPharm, Inc. (NASDAQ:KMPH) - Engelwood Daily
06/30/16 07:46 AMKemPharm Inc (NASDAQ:KMPH) Company Rating and Target Watch - Telanagana Press
06/30/16 07:46 AMHome Biotech Stocks KemPharm, Inc. | $KMPH Stock | Shares Spike Up on Positive Trial... - TickerTV News (press release)
06/29/16 04:46 PMKemPharm, Inc Stock Shares Spike Up on Positive Trial Results
06/28/16 03:31 PMKemPharm’s Prodrug of Hydromorphone, KP511, Demonstrates Comparable Oral Pharmacokinetics to Hydromorphone in Phase 1 Trial - [at noodls] - CORALVILLE, Iowa, June 28, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today ...
06/28/16 03:31 PMKemPharm’s Prodrug of Hydromorphone, KP511, Demonstrates Comparable Oral Pharmacokinetics to Hydromorphone in Phase 1 Trial - [at noodls] - CORALVILLE, Iowa, June 28, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today ...
06/28/16 03:22 PMKEMPHARM, INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/28/16 03:22 PMKEMPHARM, INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/28/16 09:43 AMNASDAQ New Lows: KemPharm, Inc. (NASDAQ:KMPH), WisdomTree Investments, Inc. (NASDAQ:WETF), Dicerna ... - KC Register
06/27/16 04:48 PMStock Volatility in Review: KemPharm, Inc. (NASDAQ:KMPH) - Engelwood Daily
06/27/16 04:48 PMShares in Oversold Area: KemPharm, Inc. (NASDAQ:KMPH) - Press Telegraph
06/27/16 09:09 AMShare Update and Earnings Review for KemPharm Inc (NASDAQ:KMPH) - Press Telegraph
06/27/16 09:09 AMNext Weeks Broker Price Targets For KemPharm, Inc. (KMPH) - Fiscal Standard
06/25/16 08:39 AMCovering the Bases on KemPharm Inc (NASDAQ:KMPH): Where is the Stock Going? - Press Telegraph
06/25/16 08:39 AMHow Many KemPharm Inc (NASDAQ:KMPH)'s Analysts Are Bearish? - Press Telegraph
06/24/16 07:28 AMKemPharm Inc (NASDAQ:KMPH) Earnings Glance and Target Price Review - Engelwood Daily
06/23/16 05:13 PMKemPharm, Inc. (KMPH) Current Analyst Ratings - Fiscal Standard
06/23/16 05:13 PMEquity Research and Technical Review on KemPharm Inc (NASDAQ:KMPH) - Press Telegraph
06/15/16 04:52 PMWhy KemPharm Inc (NASDAQ:KMPH) Shares Could Face Some Downside - Small Cap Exclusive (press release)
06/15/16 04:52 PMOppenheimer Analyst Weighs In on Two Falling Biotechs: KemPharm Inc (KMPH), Marinus Pharmaceuticals Inc (MRNS) - Smarter Analyst
06/15/16 04:52 PMKemPharm Inc. (KMPH) Dropped To A New Low After FDA Complete Response Letter - RTT News
06/15/16 09:29 AMKemPharm Inc. (KMPH) Dropped To A New Low After FDA Complete Response Letter
06/14/16 04:40 PMKemPharm Inc. (KMPH) Is Sharply Lower After FDA Complete Response Letter - RTT News
06/14/16 09:41 AMKemPharm Inc. (KMPH) Is Sharply Lower After FDA Complete Response Letter
06/13/16 04:38 PMKemPharm says U.S. FDA does not approve its painkiller - [Reuters] - KemPharm Inc said the U.S. health regulator did not approve its abuse-deterrent version of a painkiller, sending the drug developer's shares down more than 30 pct in extended trade. The U.S. Food and Drug ...
06/13/16 04:33 PMKemPharm Inc. (KMPH) Is Falling After FDA Complete Response Letter
06/13/16 04:33 PMKemPharm (KMPH) Receives FDA Complete Response Letter for Apadaz NDA
06/13/16 03:29 PMFDA Issues Complete Response Letter for Apadaz™ New Drug Application - [at noodls] - CORALVILLE, Iowa, June 13, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today ...

Social

About KemPharm

KemPharm logoKemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company's product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company's products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: KMPH
  • CUSIP:
Key Metrics:
  • Previous Close: $4.39
  • 50 Day Moving Average: $4.78
  • 200 Day Moving Average: $11.73
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $64.42M
  • Beta: -2.02
  • Current Year EPS Consensus Estimate: $-2.57 EPS
  • Next Year EPS Consensus Estimate: $-2.61 EPS
Additional Links:
KemPharm (NASDAQ:KMPH) Chart for Monday, July, 25, 2016